Eli Lilly CEO's AI-Driven Science Quest

Eli Lilly CEO David Ricks leverages AI in meetings, preferring models like Anthropics Claude and xAIs Grok for scientific inquiries. Despite AIs potential, he believes its still early days in drug development, citing the need for a more comprehensive biological knowledge base and significant investment in robotics for data generation.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.